Cover Image
市場調查報告書

腦膜炎感染疾病:開發中產品分析

Neisseria meningitidis Infections - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 293895
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
腦膜炎感染疾病:開發中產品分析 Neisseria meningitidis Infections - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 90 Pages
簡介

腦膜炎感染症是血液及髓膜(腦及脊髓上覆的薄膜)感染細菌的重大疾病,症狀有發燒,頸椎僵直,關節痛,噁心,意識障礙等。風險要素有年齡,抽煙,粘膜病變,人群,乾季·乾旱等天氣,沙塵暴,同時感染呼吸疾病等。

本報告提供全球各國治療腦膜炎感染疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

腦膜炎感染疾病概要

治療藥的開發

  • 腦膜炎感染疾病開發中產品:概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

腦膜炎感染疾病開發治療藥的企業

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • China National Pharmaceutical Group Corp
  • GlaxoSmithKline Plc
  • Griffith University
  • ImmunoBiology Ltd
  • JN-International Medical Corp
  • MGB Biopharma Ltd
  • Panacea Biotec Ltd
  • Pfizer Inc
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Wellstat Vaccines LLC

藥物簡介

腦膜炎感染疾病治療藥:開發暫停的產品

腦膜炎感染疾病治療藥:開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9251IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2017, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 2, 2, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 4 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neisseria meningitidis Infections - Overview
    • Neisseria meningitidis Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neisseria meningitidis Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Biological E Ltd
    • China National Pharmaceutical Group Corp
    • GlaxoSmithKline Plc
    • Griffith University
    • ImmunoBiology Ltd
    • JN-International Medical Corp
    • MGB Biopharma Ltd
    • Panacea Biotec Ltd
    • Pfizer Inc
    • Sanofi Pasteur SA
    • Serum Institute of India Ltd
    • Wellstat Vaccines LLC
  • Neisseria meningitidis Infections - Drug Profiles
    • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae [serotype B] + meningococcal) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MenBioVax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W135] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes C, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [strain C2135] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neisseria meningitidis [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neisseria meningitidis [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neisseria meningitidis Infections - Dormant Projects
  • Neisseria meningitidis Infections - Discontinued Products
  • Neisseria meningitidis Infections - Product Development Milestones
    • Featured News & Press Releases
      • Mar 24, 2017: Pfizer Receives Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease
      • Oct 19, 2016: CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA (Meningococcal Group B Vaccine)
      • Sep 05, 2016: 'Real world' data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme
      • May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine)
      • May 13, 2016: GSK's Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
      • May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting
      • Oct 09, 2015: Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents
      • Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine)
      • Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age
      • Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines
      • May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil
      • Mar 29, 2015: GSK statement on meningitis vaccination in the UK
      • Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk
      • Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents
      • Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Neisseria meningitidis Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Biological E Ltd, H1 2017
  • Neisseria meningitidis Infections - Pipeline by China National Pharmaceutical Group Corp, H1 2017
  • Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Griffith University, H1 2017
  • Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H1 2017
  • Neisseria meningitidis Infections - Pipeline by JN-International Medical Corp, H1 2017
  • Neisseria meningitidis Infections - Pipeline by MGB Biopharma Ltd, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Panacea Biotec Ltd, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Serum Institute of India Ltd, H1 2017
  • Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H1 2017
  • Neisseria meningitidis Infections - Dormant Projects, H1 2017
  • Neisseria meningitidis Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Neisseria meningitidis Infections - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Neisseria meningitidis Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top